Cost-Effectiveness Analysis of Duodenal–Jejunal Bypass Sleeve Device for People With Obesity
Speaker(s)
Xu Q1, Yan W2, Li L3, Liu B3
1School of Public Health, Fudan University, Shanghai, Shanghai, China, 2School of Public Health, Fudan University, Shanghai, 31, China, 3School of Public Health, Fudan University, Shanghai, China
Presentation Documents
OBJECTIVES: The aim of this study is to conduct economic evaluation of Duodenal–Jejunal Bypass Sleeve (DJBS) plus intensive lifestyle intervention (ILI) compared with ILI in people with obesity in China.
METHODS: A decision tree Markov model was used to compare 9-month and lifetime horizon cost-effectiveness between DJBS plus ILI and ILI. The data of clinical effectiveness were based on a prospective, open-label and randomized trial (NCT05938231). The willingness-to-pay (WTP) threshold was 1~3 times GDP per capita in China (GDP per capita CNY ¥85,498 yuan, 2022). One-way, probabilistic sensitivity and scenario analysis were performed to test the robustness of the results.
RESULTS: The results of 9-month decision tree model showed that compare to ILI, DJBS plus ILI decreased body mass index (BMI) by 1.69 kg/m2 (1.41 vs. 3.10), with increasing cost of CNY ¥28,963.98 yuan (CNY ¥29,111.06 vs. CNY ¥147.08). The incremental cost-effectiveness ratio (ICER) was CNY ¥17,138.45 yuan per unit decrease of BMI. The lifetime horizon model showed that compared to ILI, DJBS plus ILI had a higher cost of CNY ¥13261.94 yuan (CNY ¥ 31,688.98 vs. CNY¥18,427.04), while with life-years increase of 0.02 (9.43 vs. 9.41) and quality-adjusted life years (QALYs) increase of 0.15 (7.82 vs. 7.67) per people with obesity. The ICER was CNY ¥88,412.93 per QALY gained. Probability sensitivity analysis showed the robustness of the economic evaluation results. In addition, the ICER was CNY ¥148,218.00 for DJBS plus ILI compared to bariatric surgery.
CONCLUSIONS: The findings suggested that, compared to ILI, DJBS plus ILI is a cost-effective strategy over the lifetime horizon when the WTP threshold was 1.03 times GDP per capita.
Code
EE13
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Novel & Social Elements of Value, Thresholds & Opportunity Cost, Trial-Based Economic Evaluation
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Medical Devices